hepat
c
viru
hcv
therapi
live
revolut
hosttarget
agent
hta
block
hcv
product
interact
host
cell
compon
target
conserv
host
protein
variabl
viral
protein
hta
potenti
pangenotyp
antivir
activ
high
barrier
resist
two
hta
reach
clinic
develop
includ
specif
inhibitor
cyclophilin
peptidylprolyl
cistran
isomeras
activ
antagonist
cyclophilin
inhibitor
proven
rel
well
toler
confid
use
backbon
allor
interferonfre
regimen
addit
hta
cyclophilin
inhibitor
offer
opportun
panvir
approach
target
mechan
common
virus
differ
famili
articl
form
part
symposium
antivir
research
hepat
c
next
step
toward
global
erad
hepat
c
viru
hcv
therapi
live
revolut
four
alreadi
approv
new
antivir
agent
dozen
phase
clinic
development
stage
new
hcv
drug
split
two
group
directact
antivir
daa
target
viral
actor
hcv
lifecycl
hosttarget
agent
hta
block
hcv
product
interact
host
cell
compon
pawlotski
mani
year
hta
avail
treatment
chronic
hepat
c
includ
interferona
ifna
trigger
intracellular
cascad
event
turn
activ
number
nonspecif
antivir
cellular
effector
ribavirin
drug
acceler
infect
cell
clearanc
cure
hcv
product
potent
inhibit
yet
unknown
mechan
chevaliez
pawlotski
thoma
et
al
feld
press
koh
liang
press
recent
hta
target
host
cell
compon
involv
complex
interact
viral
protein
essenti
hcv
lifecycl
develop
hcv
lifecycl
start
receptor
bind
surfac
hepatocyt
hcv
entri
cell
phdepend
relat
clathrinmedi
endocytosi
follow
fusion
step
within
acid
endosom
compart
decapsid
viral
nucleocapsid
liber
free
positivestrand
genom
rna
cell
cytoplasm
serv
togeth
newli
synthes
rna
messeng
rna
synthesi
hcv
polyprotein
polyprotein
target
endoplasm
reticulum
membran
coand
posttransl
process
host
cell
peptidas
autocatalyt
proteas
serin
proteas
result
gener
structur
protein
c
core
viroporin
nonstructur
protein
replic
catalyz
hcv
rnadepend
rna
polymeras
rdrp
protein
protein
helicasentpas
domain
protein
play
import
regulatori
role
viru
replic
wherea
serv
membran
anchor
replic
complex
play
import
role
membran
rearrang
lead
format
viral
particl
format
initi
interact
core
protein
genom
rna
hcv
use
lipoprotein
product
pathway
gener
matur
viral
particl
export
lindenbach
lohmann
niepmann
zeisel
et
al
host
cell
protein
involv
everi
step
hcv
lifecycl
see
tabl
hcv
entri
mediat
sever
cell
surfac
tight
junction
protein
includ
lowdens
lipoprotein
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
n
v
r
l
ldl
receptor
scaveng
receptor
occludin
epiderm
growth
factor
receptor
zeisel
et
al
translat
use
cellular
ribosom
machineri
three
eukaryot
initi
factor
eif
also
recruit
noncanon
rnabind
protein
includ
la
protein
protein
hnrnp
heterogen
nuclear
ribonucleoprotein
l
insulinlik
growth
factor
mrna
bind
protein
likesm
protein
poli
rc
bind
protein
interact
viral
genom
niepmann
fixat
noncod
region
genom
appear
stimul
translat
stabil
rna
contribut
end
viral
genom
translat
appear
mediat
two
cell
protein
nfar
nuclear
factor
associ
dsrna
protein
complex
niepmann
number
host
cell
protein
shown
contribut
format
replic
complex
membran
web
lipid
kinas
phosphatidylinositol
iii
alpha
fbox
leucin
rich
repeat
protein
host
cell
lipid
lipid
droplet
lohmann
larg
number
viral
protein
involv
rna
synthesi
catalyz
viral
rdrp
control
viral
protein
shown
interact
viral
protein
requir
viral
replic
includ
cyclophilin
hvapa
human
vampassoci
protein
isoform
hvapb
cellular
rnabind
protein
lohmann
hcv
particl
assembl
share
numer
featur
vldlldl
assembl
pathway
interact
number
apolipoprotein
particular
apob
apo
mtp
microsom
triglycerid
transfer
protein
play
major
role
vldl
secret
viral
particl
product
lindenbach
addit
hcv
use
escrt
endosomalsort
complex
requir
transport
pathway
recycl
endosom
compart
number
host
cell
factor
eg
phospholipas
subunit
clathrin
adapt
protein
complex
annexin
stress
granul
protein
assembl
bud
cytoplasm
viral
particl
pass
golgi
apparatu
vampdepend
manner
lindenbach
block
interact
cell
compon
hcv
lifecycl
result
effici
blockad
viral
product
shown
vitro
specif
inhibitor
silenc
rna
thu
numer
hosttarget
approach
theoret
envisag
inhibit
hcv
replic
howev
two
reach
clinic
develop
thu
far
includ
specif
inhibitor
cyclophilin
peptidylprolyl
cistran
isomeras
activ
antagonist
class
compound
reduc
viral
replic
sever
log
administ
infect
patient
phase
ib
ii
clinic
trial
flisiak
et
al
janssen
et
al
drug
interact
lipid
metabol
statin
shown
inhibit
vitro
replic
hcv
block
late
step
hcv
lifecycl
potenti
clinic
benefit
statin
hcvinfect
patient
best
modest
oleari
et
al
patel
et
al
zhu
et
al
given
result
current
futur
antihcv
therapi
unlik
hosttarget
approach
reach
clinic
develop
indic
vast
major
new
hcv
drug
develop
daa
includ
inhibitor
proteas
nucleosidenucleotid
analogu
inhibitor
hcv
rdrp
nonnucleosid
inhibitor
rdrp
inhibitor
pawlotski
compound
potent
firstgener
drug
low
barrier
resist
notabl
except
nucleosidenucleotid
analogu
secondgener
drug
higher
barrier
resist
current
develop
pawlotski
context
place
hosttarget
agent
cure
hcv
infect
drug
regimen
must
combin
antivir
potenc
high
barrier
resist
ensur
inhibit
viru
product
sustain
full
treatment
period
case
infect
cell
progress
elimin
rna
genom
contain
cell
infect
time
treatment
withdrawn
cyclophilin
inhibitor
shown
potent
inhibit
viral
replic
vitro
vivo
flisiak
et
al
paeshuys
et
al
target
conserv
host
protein
variabl
viral
protein
cyclophilin
inhibitor
antagonist
pangenotyp
antivir
activ
high
barrier
resist
coelmont
et
al
flisiak
et
al
lanford
et
al
paeshuys
et
al
puyang
et
al
resist
report
thu
far
antagonist
vivo
howev
viral
polymorph
associ
resist
antagon
report
recent
vitro
studi
li
et
al
whether
variant
natur
exist
infect
patient
unknown
amino
acid
substitut
viral
protein
hardli
select
cyclophilin
inhibitor
numer
passag
vitro
coelmont
et
al
flisiak
et
al
lanford
et
al
paeshuys
et
al
puyang
et
al
essenti
locat
protein
sequenc
confer
minor
reduct
drug
suscept
vitro
appear
play
role
cyclophilin
inhibitor
treatment
failur
vivo
hta
thu
repres
ideal
backbon
pangenotyp
drug
combin
potent
antivir
activ
high
barrier
resist
firstlin
use
patient
hosttarget
antihcv
approach
howev
caveat
theori
target
host
cellular
function
may
essenti
cell
surviv
toxic
peptidylprolyl
cistran
isomeras
activ
cyclophilin
catalyz
isomer
peptid
bond
prolin
residu
facilit
protein
fold
howev
mice
knockedout
cyclophilin
viabl
even
seem
protect
lethal
heart
ischemiareperfus
injuri
belaidi
et
al
clinic
practic
administr
alisporivir
cyclophilin
inhibitor
deriv
cyclosporin
current
phase
ii
clinic
develop
associ
mild
moder
hyperbilirubinemia
dosedepend
revers
upon
treatment
withdraw
hyperbilirubinemia
mix
due
inhibit
uptak
unconjug
bilirubin
transport
organ
anion
transport
bilirubin
conjug
bilirubin
efflux
transport
canalicular
multispecif
organ
anion
transport
without
inhibit
glucuronid
conjug
flisiak
et
al
pawlotski
et
al
alisporivir
administr
also
associ
hypertriglyceridemia
pawlotski
et
al
may
aggrav
acut
pancreat
case
occur
combin
ifna
includ
one
fatal
case
reason
clinic
efficaci
alisporivir
current
studi
part
ifnfre
combin
side
effect
observ
week
administr
miravirsen
antagonist
janssen
et
al
howev
concern
rais
longterm
effect
inhibit
low
level
hepatocyt
report
associ
hepatocellular
carcinoma
tsai
et
al
theoret
approach
target
host
cell
function
involv
hcv
lifecycl
lead
expect
unexpect
side
effect
must
note
howev
unexpect
sometim
seriou
advers
event
specif
hta
numer
side
effect
report
inhibitor
differ
class
hcv
daa
develop
sever
compound
halt
earli
seriou
advers
event
includ
fatal
case
largescal
use
two
firstgener
proteas
inhibitor
telaprevir
boceprevir
combin
pegyl
ifna
ribavirin
associ
frequent
side
effect
particular
toxic
patient
advanc
liver
diseas
hezod
et
al
final
daa
current
clinic
develop
entir
safe
overal
past
year
hcv
drug
develop
hta
directli
target
host
cell
compon
involv
hcv
lifecycl
appear
substanti
toxic
daa
high
barrier
resist
hta
mean
contrast
daa
antivir
effect
poorli
influenc
viral
genet
polymorph
howev
hta
expos
host
genet
polymorph
may
alter
abil
block
target
protein
function
clinic
practic
patient
suboptim
antivir
respons
alisporivir
pawlotski
et
al
underli
mechan
unknown
work
need
understand
genet
basi
primari
nonrespons
hosttarget
approach
drugdrug
interact
possibl
hta
like
daa
depend
metabol
pathway
use
mode
administr
also
issu
cyclophilin
inhibitor
administ
oral
antagonist
miravirsen
must
inject
clear
disadvantag
era
allor
therapi
janssen
et
al
futur
hosttarget
approach
need
oral
administ
hosttarget
approach
fit
hcv
drug
armamentarium
current
viabl
approach
seem
cyclophilin
inhibit
inde
cyclophilin
inhibitor
confid
use
backbon
allor
ifnfre
regimen
potenc
pangenotyp
activ
high
barrier
resist
good
toler
absenc
ifna
coadministr
recent
studi
show
alisporivir
synergist
effect
vitro
differ
famili
daa
garciarivera
et
al
thu
drug
regimen
combin
cyclophilin
inhibitor
proteas
inhibitor
rdrp
inhibitor
andor
inhibitor
without
ribavirin
credibl
like
enter
clinic
evalu
soon
whether
hosttarget
approach
investig
treatment
hcv
infect
debat
respect
interest
note
drug
industri
current
disinvest
new
hcv
drug
screen
optim
belief
enough
drug
market
soon
fulfil
clinic
need
hta
target
host
factor
involv
viral
lifecycl
viru
potenti
broader
indic
daa
natur
activ
hcv
cyclophilin
inhibitor
shown
inhibit
replic
hepat
b
viru
hiv
coronavirus
frausto
et
al
phillip
et
al
tanaka
et
al
hosttarget
antivir
approach
offer
opportun
panvir
antivir
approach
target
mechan
common
virus
belong
differ
famili
given
number
viral
infect
repres
import
public
health
problem
specif
antivir
compound
exist
like
develop
shortto
midterm
research
hosttarget
approach
combat
viral
infect
encourag
learnt
year
hcv
research
drug
develop
may
particularli
use
respect
make
hcv
invalu
model
futur
antivir
drug
develop
author
receiv
research
grant
gilead
scienc
serv
advisor
abbott
abbvi
achillion
boehringeringelheim
bristolmy
squibb
gilead
scienc
idenix
janssen
merck
novarti
roch
